MARTIN TAMOU: Open Payments
NPI 1114785953 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$938 in 41 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $454 · 2025 $938
Food & beverage: $938
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 10 | $260 |
| Teva Pharmaceuticals USA, Inc. | 8 | $195 |
| ABBVIE INC. | 9 | $176 |
| Neurocrine BioSciences, Inc. | 4 | $90 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $49 |
| Janssen Pharmaceuticals, Inc | 2 | $45 |
| Lundbeck LLC | 2 | $37 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
Products named: FANAPT, VRAYLAR, AUSTEDO XR, INGREZZA, ABILIFY ASIMTUFII, CAPLYTA, UZEDY, REXULTI.
Industry payments across AZ — which companies pay providers there.
